| Outcome Measures: |
Primary: Cumulative incidence of New Onset of Diabetes After Transplantation(NODAT), 12 month after transplantation | Secondary: Cumulative incidence of NODAT, 3, 6, 24 month after transplantation|Composite measure, Freedom from acute rejection, graft and patient survival, 12, 24 months|Renal function, Evaluated by measured glomerular filtration rate (mGFR), 12, 24 months|Incidence of acute rejection and chronic changes, Analysed by protocol biopsies, evaluated by the Banff system., 12 months|Incidence of hypertension, Standardized measurement., 3, 12, 24 months|Antihypertensive treatment, Number and type of antihypertensive drugs., 3, 12, 24 months|Lipid lowering drugs, Number and type of lipid lowering drugs., 12, 24 months|Incidence of antibody-mediated rejection, Analysed by biopsies, evaluated by the Banff system, and by donor-specific HLA antibodies, 12, 24 months|Cumulative frequency of cardiovascular complications and events., Collecting Adverse Events (AE) reports, 10 days, 3, 12, 24 months|Cumulative frequency of malignancy., Collecting AE reports, 6, 12, 24 months|Cumulative frequency of infections, Collecting AE reports, 10 days, 3, 6, 12, 24 months
|
